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Background: Decreased LVEF at presentation during STEMI has been established as
a predictor of morbidity and mortality. Many patients have improvement in LVEF
over time due to recovery of hibernating or stunned myocardium. Little data exists on
the clinical and angiographic predictors of improvement in LVEF after stenting.
Methods: In HORIZONS-AMI, 3,602 patients presenting with STEMI at 123 sites
were randomized to heparin + a glycoprotein IIb/IIIa inhibitor (H+GPI) vs. bivalir-
udin, and to paclitaxel-eluting stents vs. bare metal stents. Clinical follow-up was
performed for three years, including routine angiographic follow-up at 13 months in a
pre-speciﬁed substudy.
Results: Baseline and 13-month follow-up LVEF measurements were available in 656
patients, comprising the current study cohort. The median change [interquartile range]
in LVEF from baseline to 13 months was +2.4% [-5.85%, 11.80%]. During follow-up
LVEF rose or remained the same in 379 (57.8%) patients (median D +9.8% [4.30%,
16.40%]), and fell in 277 (42.2%) patients (median D -7.0% [-11.80%, -3.60%]). By
multivariable analysis, independent predictors of improvement in LVEF were female
sex (p¼0.002) and TIMI 3 ﬂow after PCI (p¼0.03), while longer lesion length
(p¼0.04), greater peak CKMB (p< 0.0001) and higher baseline LVEF (p< 0.0001)
predicted LVEF decrease (Table). Of note, use of drug-eluting vs. bare metal stents,
bivalirudin vs. H+GPI, symptom-to-balloon time, and discharge use of beta-blockers
or ACEI/ARBs were not signiﬁcant predictors of LVEF improvement.Table. Multivariable Correlates of LVEF Improvement from Baseline to
13 Months
Multivariable Correlates Odds Ratio [95% CI] (adjusted) P Value
Female sex 2.08 [1.3, 3.33] 0.002
Baseline LVEF 0.90 [0.88, 0.91] <0.0001
Peak CKMB 1.00 [1.00, 1.00] <0.0001
TIMI 3 ﬂow post-PCI 1.96 [1.06, 3.62] 0.03
Total lesion length 0.98 [0.97, 1.00] 0.04
B6 JACC Vol 64/11/Suppl B jConclusions: While LVEF improves during follow-up in more than half of patients
after primary PCI, a signiﬁcant proportion have worsening LV function over time.
Further approaches are required to improve myocardial recovery after mechanical
reperfusion therapy in STEMI.
TCT-19
Predictors of Target Vessel Revascularization after Primary Percutaneous
Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction:
Lessons from HORIZONS-AMI
Sorin Brener1, Roxana Mehran2, Konstanze Ertelt3, Philippe Genereux4, Ke Xu5,
Bernhard Witzenbichler6, Gregg W. Stone7
1New York Methodist Hospital, Brooklyn, United States, 2Icahn School of Medicine at
Mount Sinai,, New York, NY, 3Cardiovascular Research Foundation, New York City,
NY, 4Columbia University Medical Center, New York, 5Cardiovascular Research
Foundation, New York, NY, 6Charité Campus Benjamin Franklin, Berlin, Germany,
7Columbia University Medical Center and the Cardiovascular Research Foundation,
New York, United States
Background: Primary percutaneous coronary intervention (PCI) is the preferred
method of reperfusion in ST-segment elevation myocardial infarction (STEMI).
Target vessel revascularization (TVR) due to restenosis or disease progression may
compromise the beneﬁts of primary PCI. The predictors and impact of TVR after
STEMI are not well understood.
Methods: In HORIZONS AMI 3,602 patients with STEMI were randomized to
bivalirudin vs. heparin and a glycoprotein IIb/IIIa inhibitor; stents were implanted in
3,202 patients. Ischemia-driven TVR of the infarct-related artery (IRA) required
recurrent angina and/or signs of ischemia and 50% diameter restenosis, or 70%
diameter stenosis even in the absence of ischemia.
Results: TVR occurred in 219 (6.9%) patients at 1 year, 392 (12.9%) at 2 years, and 437
(14.4%) at 3 years. Repeat PCI was performed in 410 (93.0%) patients and CABG in 48
(11.4%, not mutually exclusive). TVRwas ischemia-driven in 418 patients (95.7%). TVR
was due to restenosis in 343 patients (80.2%) and disease progression in 94 (19.8%). Pa-
tients with vs. without TVR had similar rates of death (6.6% vs. 6.3%, P¼0.87), but
markedly higher rates ofMI (35.3% vs. 2.7%, P< 0.0001) and non-CABGmajor bleeding
(13.8%vs. 7.8%, P< 0.001). Of the 151MI events in the TVR group, 29 (19.2%) occurred
before (average 35 days) TVR, 13 (8.6%) occurred after (average 166 days) TVR, and the
rest (72.2%) occurred on same day asTVR.Half of theMIs beforeTVRoccurredwithin 48
hours of it, suggesting that TVRwas the result of theMI. Target lesion deﬁnite SToccurred
in 29.2% of TVR patients and in 0.4% of non-TVR group, P< 0.0001. Only one third of
them occurred beyond 1 year. Independent predictors of TVR were more extensive CAD
(HR¼1.18 per diseased vessel, P¼0.006), smaller vessel size (HR¼1.37 per mm,
P¼0.006), longer lesion length (HR¼1.01 per mm, P¼0.003), scheduled angiographic
follow-up (HR¼1.41, P¼0.001) and treatment with bare metal rather than drug-eluting
stents (HR¼1.59, P< 0.0001).
Conclusions: TVR occurs in 1 of every 7 STEMI patients within 3 years after primary
PCI, is usually due to restenosis rather than disease progression, and is strongly related
to adverse outcomes (but not death).
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Background: Myocardial perfusion is impaired in up to 40% of patients after primary
PCI (pPCI) for ST-segment elevation myocardial infarction (STEMI), which is asso-
ciated with adverse clinical outcomes. Pressure-controlled intermittent coronary sinus
occlusion (PICSO) aims to improvemicrovascular perfusion after pPCI by intermittently
increasing the pressure in the cardiac venous outﬂow tract by means of a balloon-tipped
catheter in the coronary sinus.We evaluated the safety and feasibility of adjuvant PICSO
after pPCI for STEMI, and its effects on infarct size and myocardial function.
Methods: We enrolled 30 patients after successful pPCI for anterior STEMI. PICSO
for 90 minutes was attempted, and the quantity of PICSO therapy provided throughout
the procedure was documented (mm Hg of coronary sinus pressure modulation).
Infarct size and myocardial function were assessed by cardiovascular magnetic
resonance (CMR) at 2-5 days and 4-months post-pPCI, and the results were compared
with a matched historical control group.
Results: PICSO could be initiated in 19 patients (63%). Major adverse safety events
occurred in 1 patient (3%). When PICSO could be initiated, median PICSO duration was
88.8 min (Q1–Q3: 72.0–89.6 min), and could be maintained for 90(2) minutes in 12
patients (40%). However, the quantity of PICSO therapy varied from 15 to 2735 mmHgSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
